Huntington’s disease research news. In plain language. Written by scientists. For the global HD community.

Are you looking for our logo? You can download our logo and get information about how to use it on our sharing page

Articles with the topic: clinical-trial

How NOT to write a news article about a clinical trial

How NOT to write a news article about a clinical trial

Dr Jeff Carroll on March 11, 2016

A recent article in the UK newspaper the Daily Telegraph has HD families very excited. The title, "First drug to reverse Huntington’s disease begins human trials", certainly sounds exciting! But what's really going on? HDBuzz is here to help us untangle hope from hype in the huntingtin lowering world.

Huntington's Disease Therapeutics Conference 2016 - day 2

Huntington's Disease Therapeutics Conference 2016 - day 2

Dr Jeff Carroll on February 28, 2016

After an exciting day of science yesterday, day 2 saw updates on strategies to rid cells of the harmful mutant huntingtin protein and exciting reports on current and planned clinical trials.

Looking Past the Spin: Results from a Clinical Trial of Cysteamine

Looking Past the Spin: Results from a Clinical Trial of Cysteamine

Melissa Christianson on December 18, 2015

In early December, Raptor Pharmaceuticals released clinical trial results evaluating a drug called cysteamine in Huntington’s disease. News headlines about this trial are heavy on media spin, and so HDBuzz is here to break down what these new results really mean for the Huntington's community.

Liftoff: First humans treated with gene silencing drugs for HD!

Liftoff: First humans treated with gene silencing drugs for HD!

Dr Jeff Carroll on October 22, 2015

Today brings news that the first Huntington's Disease patients have been successfully dosed with gene silencing drugs targeting the HD gene. These brave volunteers are the first HD patients to ever be treated with drugs designed to attack HD at its root cause, a treatment approach with huge potential. What about this news has us so excited?

HDBuzz primer: Clinical trial designs and phases

HDBuzz primer: Clinical trial designs and phases

Dr Jeff Carroll and Melissa Christianson on October 09, 2015

The last few years have been full of announcements about the results of clinical trials for HD drugs, but it can be surprisingly hard to understand what these results actually mean. What seems like a simple question – did a drug work or not – turns out to be more complicated than you'd expect. HDBuzz is here to help HD families untangle hope from hype when it comes to clinical trial announcements.

Measuring harmful huntingtin protein in the brain’s bath water

Measuring harmful huntingtin protein in the brain’s bath water

Dr Michael Orth on May 18, 2015

Exciting technologies such as gene silencing are being developed for the treatment of Huntington’s disease. Aside from waiting for disease progression to take place, how will we know whether they are working? This has been a major hurdle for HD researchers, but we now have a super-sensitive method to measure the build-up of harmful huntingtin protein in the nervous systems of HD patients.

2015 Huntington's Disease Therapeutics Conference: Day 2

2015 Huntington's Disease Therapeutics Conference: Day 2

Dr Jeff Carroll on February 26, 2015

Our second update from the Annual Huntington's Disease Therapeutics Conference.

Can this synthetic oil help feed the brain in Huntington's disease?

Can this synthetic oil help feed the brain in Huntington's disease?

Dr Jeff Carroll on January 15, 2015

The brains of Huntington's disease patients seem to have problems making enough energy. Giving brains an energy boost might help with HD, but getting extra fuel into the brain is difficult. A new study from France reveals that feeding HD patients a special kind of fat improved their brain's energy levels. This opens the door for new studies to test whether this improvement in energy could help with HD symptoms.

Positive results announced for re-worked tetrabenazine drug in Huntington's disease

Positive results announced for re-worked tetrabenazine drug in Huntington's disease

Dr Jeff Carroll on December 22, 2014

Auspex Pharmaceuticals just announced the results of two clinical trials known as 'First-HD' and 'Arc-HD'. These trials were designed to test a modified version of the approved Huntington's disease drug tetrabenazine, which reduces unwanted movements. The results reveal that Auspex's drug has some advantages compared to tetrabenazine for treating excessive movements in HD.